Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. - Wikidata - awgldk - TriplyDB

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

http://www.wikidata.org/entity/Q33988752

about

Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.Prevention of diabetic nephropathy in Ins2(+/)⁻(AkitaJ) mice by the mitochondria-targeted therapy MitoQ.Models of chronic kidney disease Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial.Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.Development and use of sulodexide in vascular diseases: implications for treatment.Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies.A conceptual framework for the molecular pathogenesis of progressive kidney disease.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.Biophysics of glomerular filtration.Sulodexide Protects Renal Tubular Epithelial Cells from Oxidative Stress-Induced Injury via Upregulating Klotho Expression at an Early Stage of Diabetic Kidney Disease The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing.

P2860

Q28083781-660354AC-2564-4C50-86BE-97711188EBFE Q30423005-85B74313-1E5C-4240-927E-D55F7F3AA05C Q34277437-EFC955AF-20B8-400F-9AC7-2D565ED60DC1 Q34536492-C964ADE0-5AA5-4392-B2A2-ABEC9E13E74E Q34563204-67FC318C-2217-48C2-8753-240870A2A2B3 Q35412466-AA9A7DB8-7F20-4A48-A512-EF00B8FC16D7 Q35720773-F400ACF9-C0A5-4481-B25A-504F054B4C42 Q37284133-C8B0C0D7-B64C-484E-AF7C-B0B1AAF53F8A Q37427653-D3BD1858-1191-4F67-859A-FA3A387799E6 Q37705263-4D6DC6BA-71FD-4A5A-BE62-61E20E09684F Q37721284-67FAB8A2-2D71-4381-9B24-6B0F847968A5 Q37904098-72A56767-928E-4989-82A9-C4FBFB59F9FE Q38087529-002340F3-160D-4B8B-B170-FBF7FA8BDEEE Q38110744-A8571102-6849-443D-BE3D-E412AB2842E9 Q41449615-67676854-9EE0-48C8-ABD1-513C902E106C Q41989543-CD004AEF-5B90-43C9-8F4C-9E476CB33484

P2860

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

http://www.wikidata.org/entity/Q33988752

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@ast

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@en

type

label

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@ast

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@en

prefLabel

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@ast

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@en

P1433

Q33988752-D7C853A5-2994-4EAF-85DC-EBAFC197626D

P1476

Q33988752-C736CEA4-F73C-487B-88C3-42B52D3DEDD7

P2093

Q33988752-0D49F64E-EFC5-4276-844B-F2A8849B1947

Q33988752-0EEC6F26-F3CF-4DF6-B2EA-AB2E6221994C

Q33988752-2AA68C14-75F6-4578-ADCB-CE63753F4185

Q33988752-33477668-53B5-4DC4-BC9F-F3078687F77B

Q33988752-8D28D364-4261-4E14-AD80-F467ECD7E313

Q33988752-C02A0446-6FFA-4FF1-9941-C24B35E3E173

Q33988752-C3A66D41-A1F6-4D61-9314-BC16D45FF75B

Q33988752-FB1F0B40-6B5E-4A71-93BB-8930B70D414C

Q33988752-FE60D754-781C-4D45-960B-7D54C4CFF10C

P2860

Q33988752-026AC641-3331-4ECD-9A2A-1A49436A0DBF

Q33988752-1F0C6DFB-3174-40D3-B563-9EDEAFF754F3

Q33988752-200AF361-84AD-4926-A8D7-A4A475E13C28

Q33988752-20C00CCD-C1ED-445E-941A-F4DB3289EF53

Q33988752-2F4CC3BC-2EFE-4140-9C9E-80BDD3ACE23C

Q33988752-3725BC68-6218-4F30-A32C-2F19360F6AAE

Q33988752-3A6F34D7-1D5F-4495-92D6-A3D4876AE7E2

Q33988752-3BA55AA4-4377-4125-875A-FD66E81A1174

Q33988752-3FED3D73-8020-496C-BC58-894242B2562A

Q33988752-4988AA46-A29C-48D1-9F1B-9C9B865F5358

P304

Q33988752-AEC4B31E-1B35-4B41-BBDD-B73D799E7DC9

P31

Q33988752-41E7692C-55B3-4493-B7F3-738229F794D9

P356

Q33988752-DD2495A0-8C1E-4C3E-AE93-6EFCFE20A27C

P407

Q33988752-7D31A347-E553-4F77-8F5F-47B8E3881EA5

P433

Q33988752-1F14B3D8-86D1-490A-A72B-A22D85C6A670

P478

Q33988752-92B64F1B-87E5-43E7-B99D-DD2493B538DB

P577

Q33988752-A0F90A11-8E74-411E-9EB8-4173E145A8CF

P5875

Q33988752-44A7530C-06C9-4351-9513-8EF351E82401

P698

Q33988752-2AA6DCC1-1D6F-4635-9255-1698973AEC99

P932

Q33988752-66B18965-FC46-4F58-A7B6-029EA51C112C

P356

P1433

Nephrology Dialysis Transplantation

P1476

Sulodexide ameliorates early b ...... athy and diabetic nephropathy.

@en

P2093

Agnes B Fogo

http://www.w3.org/2001/XMLSchema#string

Ellen Donnert

http://www.w3.org/2001/XMLSchema#string

Haichun Yang

http://www.w3.org/2001/XMLSchema#string

Kumar Sharma

http://www.w3.org/2001/XMLSchema#string

Li-Jun Ma

http://www.w3.org/2001/XMLSchema#string

Michael Freeman

http://www.w3.org/2001/XMLSchema#string

Michele Rossini

http://www.w3.org/2001/XMLSchema#string

Stephen R Dunn

http://www.w3.org/2001/XMLSchema#string

Takashi Naito

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature

Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide.

Diabetic kidney disease in the db/db mouse.

Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis.

Sulodexide: a renewed interest in this glycosaminoglycan.

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.

Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice.

Decorin deficiency enhances progressive nephropathy in diabetic mice.

Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice.

P304

1803-1810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFP724

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40899062

http://www.w3.org/2001/XMLSchema#string

P698

20061322

http://www.w3.org/2001/XMLSchema#string

P932

2902889

http://www.w3.org/2001/XMLSchema#string